Strides Pharma, Amneal Pharmaceuticals partner to launch Icosapent ethyl capsules

Strides Pharma Science Limited (“Strides”) has joined forces with Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) to introduce Icosapent ethyl acid soft gel capsules to the market. This new product, referencing VASCEPA®, is set to be commercialized by Amneal starting in the fourth quarter of 2023. The in-licensing of this product from Strides, a global pharmaceutical manufacturer, marks a significant step in the companies’ collaboration efforts.

Icosapent Ethyl: A Solution for Hypertriglyceridemia

Icosapent ethyl acid soft gel capsules, available in 0.5g and 1g dosages, are designed as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL). The active ingredient, an ethyl ester of eicosapentaenoic acid (EPA), is a targeted solution for managing high triglyceride levels, a common health concern globally.

Strides and Amneal’s Commitment to Healthcare Excellence

Aditya Kumar, Vice President of Business Development at Strides Pharma Science Limited, expressed enthusiasm about the partnership with Amneal Pharmaceuticals. He emphasized that this collaboration reflects both companies’ commitment to excellence and the pursuit of innovative healthcare solutions. The partnership aims to benefit not only the organizations but also customers and stakeholders.

Amneal’s Expanding Product Portfolio in 2023

Andy Boyer, Executive Vice President of Amneal Generics, highlighted the company’s plan to launch over 40 new products in 2023. The addition of Icosapent ethyl to Amneal’s portfolio is a testament to their dedication to providing essential medicines and expanding their offerings in the pharmaceutical industry.

This collaboration between Strides Pharma Science and Amneal Pharmaceuticals underscores a significant development in the healthcare sector, promising to bring forth innovative treatments for conditions like hypertriglyceridemia.